SRPT vs TRDA
SRPT: Sarepta Therapeutics is a leader in genetic medicine, specializing in innovative RNA-targeted and gene therapies to treat rare neuromuscular diseases like Duchenne muscular dystrophy. TRDA: Entrada Therapeutics is developing a new class of intracellular genetic medicines using its proprietary endosomal escape vehicle technology to treat serious neuromuscular and retinal diseases.
Side-by-side fundamentals
| Metric | SRPT | TRDA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $18.21 | $5.53 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $1.9B | $215M | |
| Net margin FY2025, SEC XBRL | -32.5% | -565.5% | SRPT higher |
| Operating margin FY2025, SEC XBRL | -31.8% | -621.1% | SRPT higher |
| ROE FY2025, SEC XBRL | -62.5% | -47.0% | TRDA higher |
| ROA FY2025, SEC XBRL | -21.3% | -38.1% | SRPT higher |
| Debt / equity as of 2026-09-02 | 0.55 | 0.00 | TRDA lower |
| Revenue growth (YoY) as of 2026-09-02 | -20.4% | -94.1% | SRPT higher |
| Revenue CAGR (3y) SEC XBRL | +33.1% | -55.6% | SRPT higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.56 | 1.18 | |
| 1-year return as of 2026-10-08 close | -22.1% | -10.2% | TRDA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.